- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 186068, 11 pages
Modulation of Neurological Deficits and Expression of Glutamate Receptors during Experimental Autoimmune Encephalomyelitis after Treatment with Selected Antagonists of Glutamate Receptors
Laboratory of Pathoneurochemistry, Department of Neurochemistry, Mossakowski Medical Research Centre, Polish Academy of Sciences, 5 Pawińskiego Street, 01-106 Warsaw, Poland
Received 5 April 2013; Accepted 2 June 2013
Academic Editor: George Perry
Copyright © 2013 Grzegorz Sulkowski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- A. J. Groom, T. Smith, and L. Turski, “Multiple sclerosis and glutamate,” Annals of the New York Academy of Sciences, vol. 993, pp. 229–275, 2003.
- D. Pitt, P. Werner, and C. S. Raine, “Glutamate excitotoxicity in a model of multiple sclerosis,” Nature Medicine, vol. 6, no. 1, pp. 67–70, 2000.
- J. J. G. Geurts, G. Wolswijk, L. Bö et al., “Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis,” Brain, vol. 126, no. 8, pp. 1755–1766, 2003.
- D. W. Choi, “Calcium and excitotoxic neuronal injury,” Annals of the New York Academy of Sciences, vol. 747, pp. 162–171, 1994.
- J. M. H. Anneser, G. Domenico Borasio, A. Berthele, W. Zieglgänsberger, and T. R. Tölle, “Differential expression of group I metabotropic glutamate receptors in rat spinal cord somatic and autonomic motoneurons: possible implications for the pathogenesis of amyotrophic lateral sclerosis,” Neurobiology of Disease, vol. 6, no. 2, pp. 140–147, 1999.
- S. R. Bradley, M. J. Marino, M. Wittmann et al., “Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia nigra pars reticulata,” The Journal of Neuroscience, vol. 20, no. 9, pp. 3085–3094, 2000.
- V. Brunos, A. Copani, T. Knöpfel et al., “Activation of metabotropic glutamate receptors coupled to inositol phospholipid hydrolysis amplifies NMDA-induced neuronal degeneration in cultured cortical cells,” Neuropharmacology, vol. 34, no. 8, pp. 1089–1098, 1995.
- S. D'Antoni, A. Berretta, G. Seminara et al., “A prolonged pharmacological blockade of type-5 metabotropic glutamate receptors protects cultured spinal cord motor neurons against excitotoxic death,” Neurobiology of Disease, vol. 42, no. 3, pp. 252–264, 2011.
- A. Pisani, P. Gubellini, P. Bonsi et al., “Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons,” Neuroscience, vol. 106, no. 3, pp. 579–587, 2001.
- Y. Ganor, M. Besser, N. Ben-Zakay, T. Unger, and M. Levite, “Human T cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migration,” Journal of Immunology, vol. 170, no. 8, pp. 4362–4372, 2003.
- R. Anwyl, “Metabotropic glutamate receptors: electrophysiological properties and role in plasticity,” Brain Research Reviews, vol. 29, no. 1, pp. 83–120, 1999.
- L. Mao and J. Q. Wang, “Group I metabotropic glutamate receptor-mediated calcium signalling and immediate early gene expression in cultured rat striatal neurons,” The European Journal of Neuroscience, vol. 17, no. 4, pp. 741–750, 2003.
- A.-M. White, R. A. Kylänpää, L. A. Christie, S. J. McIntosh, A. J. Irving, and B. Platt, “Presynaptic group I metabotropic glutamate receptors modulate synaptic transmission in the rat superior colliculus via 4-AP sensitive K+ channels,” British Journal of Pharmacology, vol. 140, no. 8, pp. 1421–1433, 2003.
- J. Perroy, F. Raynaud, V. Homburger et al., “Direct interaction enables cross-talk between ionotropic and group I metabotropic glutamate receptors,” Journal of Biological Chemistry, vol. 283, no. 11, pp. 6799–6805, 2008.
- C. Paul and C. Bolton, “Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine,” Journal of Pharmacology and Experimental Therapeutics, vol. 302, no. 1, pp. 50–57, 2002.
- S. L. Erdo and M. Schaffer, “Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate,” European Journal of Pharmacology, vol. 198, no. 2-3, pp. 215–217, 1991.
- E. Ziemińska, A. Stafiej, and J. W. Łazarewicz, “Role of group I metabotropic glutamate receptors and NMDA receptors in homocysteine-evoked acute neurodegeneration of cultured cerebellar granule neurones,” Neurochemistry International, vol. 43, no. 4-5, pp. 481–492, 2003.
- D. Makarewicz, M. Duszczyk, R. Gadamski, W. Danysz, and J. W. Łazarewicz, “Neuroprotective potential of group I metabotropic glutamate receptor antagonists in two ischemic models,” Neurochemistry International, vol. 48, no. 6-7, pp. 485–490, 2006.
- M. Kerschensteiner, C. Stadelmann, B. S. Buddeberg et al., “Animal model—targeting experimental autoimmune encephalomyelitis lesions to a predetermined axonal tract system allows for refined behavioral testing in an animal model of multiple sclerosis,” American Journal of Pathology, vol. 164, no. 4, pp. 1455–1469, 2004.
- R. Meyer, R. Weissert, R. Diem et al., “Acute neuronal apoptosis in a rat model of multiple sclerosis,” The Journal of Neuroscience, vol. 21, no. 16, pp. 6214–6220, 2001.
- M. Ohgoh, T. Hanada, T. Smith et al., “Altered expression of glutamate transporters in experimental autoimmune encephalomyelitis,” Journal of Neuroimmunology, vol. 125, no. 1-2, pp. 170–178, 2002.
- O. H. Lowry, N. J. Rosenbrough, A. L. Farr, and R. J. Randal, “Protein measurement with the Folin phenol reagent,” The Journal of Biological Chemistry, vol. 193, no. 1, pp. 265–275, 1951.
- U. K. Laemmli, “Cleavage of structural proteins during the assembly of the head of bacteriophage T4,” Nature, vol. 227, no. 5259, pp. 680–685, 1970.
- G. D. Zeevalk and W. J. Nicklas, “Evidence that the loss of the voltage-dependent Mg2+ block at the N- methyl-D-aspartate receptor underlies receptor activation during inhibition of neuronal metabolism,” Journal of Neurochemistry, vol. 59, no. 4, pp. 1211–1220, 1992.
- K. Mitosek-Szewczyk, G. Sulkowski, Z. Stelmasiak, and L. Struzyńska, “Expression of glutamate transporters GLT-1 and GLAST in different regions of rat brain during the course of experimental autoimmune encephalomyelitis,” Neuroscience, vol. 155, no. 1, pp. 45–52, 2008.
- P. K. Stys and S. A. Lipton, “White matter NMDA receptors: an unexpected new therapeutic target?” Trends in Pharmacological Sciences, vol. 28, no. 11, pp. 561–566, 2007.
- G. Sulkowski, B. Dąbrowska-Bouta, B. Kwiatkowska-Patzer, and L. Struzyńska, “Alterations in glutamate transport and group I metabotropic glutamate receptors in the rat brain during acute phase of experimental autoimmune encephalomyelitis,” Folia Neuropathologica, vol. 47, no. 4, pp. 329–337, 2009.
- I. N. Abdurasulova, S. E. Serdyuk, and V. E. Gmiro, “Combined blockade of GLUR1 AMPA and NMDA receptors effectively eliminates neurological disorders in rats with experimental allergic encephalomyelitis,” Eksperimental'naya i Klinicheskaya Farmakologiya, vol. 70, no. 4, pp. 15–19, 2007.
- G. Battaglia, V. Bruno, A. Pisani et al., “Selective blockade of type-1 metabotropic glutamate receptors induces neuroprotection by enhancing gabaergic transmission,” Molecular and Cellular Neuroscience, vol. 17, no. 6, pp. 1071–1083, 2001.
- P. Popoli, A. Pintor, M. T. Tebano et al., “Neuroprotective effects of the mGlu5R antagonist MPEP towards quinolinic acid-induced striatal toxicity: involvement of pre- and post-synaptic mechanisms and lack of direct NMDA blocking activity,” Journal of Neurochemistry, vol. 89, no. 6, pp. 1479–1489, 2004.
- M. J. Berridge, M. D. Bootman, and P. Lipp, “Calcium—a life and death signal,” Nature, vol. 395, no. 6703, pp. 645–648, 1998.
- H.-S. V. Chen, J. W. Pellegrini, S. K. Aggarwal et al., “Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity,” The Journal of Neuroscience, vol. 12, no. 11, pp. 4427–4436, 1992.
- H.-S. V. Chen and S. A. Lipton, “The chemical biology of clinically tolerated NMDA receptor antagonists,” Journal of Neurochemistry, vol. 97, no. 6, pp. 1611–1626, 2006.
- R. Sandyk, G. Awerbuch, and G. Subramanian, “Failure of amantadine hydrochloride to alter immune responses in the experimental allergic encephalomyelitis model of neuroautoimmune disease,” The International Journal of Neuroscience, vol. 40, no. 3-4, pp. 303–306, 1988.
- C. Volbracht, J. van Beek, C. Zhu, K. Blomgren, and M. Leist, “Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity,” The European Journal of Neuroscience, vol. 23, no. 10, pp. 2611–2622, 2006.
- E. Zieminska and J. W. Lazarewicz, “Excitotoxic neuronal injury in chronic homocysteine neurotoxicity studied in vitro: the role of NMDA and group I metabotropic glutamate receptors,” Acta Neurobiologiae Experimentalis, vol. 66, no. 4, pp. 301–309, 2006.
- B. Elahi, N. Phielipp, and R. Chen, “N-methyl-D-aspartate antagonists in levodopa induced dyskinesia: a meta-analysis,” The Canadian Journal of Neurological Sciences., vol. 39, no. 4, pp. 465–472, 2012.
- T. N. Fedorova, G. K. H. Bagyeva, I. S. Dobrotvorskaia et al., “Mexidant increases the effectiveness of levadopa treatment of Parkinson’s disease,” Eksprimental’naia i Klinicheskaia. Farmakologiia, vol. 75, no. 6, pp. 23–26, 2012 (Russian).
- A. Losonczy, P. Somogyi, and Z. Nusser, “Reduction of excitatory postsynaptic responses by persistently active metabotropic glutamate receptors in the hippocampus,” Journal of Neurophysiology, vol. 89, no. 4, pp. 1910–1919, 2003.
- A. M. Watabe, H. J. Carlisle, and T. J. O'Dell, “Postsynaptic induction and presynaptic expression of group 1 mGluR-dependent LTD in the hippocampal CA1 region,” Journal of Neurophysiology, vol. 87, no. 3, pp. 1395–1403, 2002.
- A. Fazal, F. Parker, A. M. Palmer, and M. J. Croucher, “Characterisation of the actions of group I metabotropic glutamate receptor subtype selective ligands on excitatory amino acid release and sodium-dependent re-uptake in rat cerebrocortical minislices,” Journal of Neurochemistry, vol. 86, no. 6, pp. 1346–1358, 2003.
- D. Manahan-Vaughan, “Group 1 and 2 metabotropic glutamate receptors play differential roles in hippocampal long-term depression and long-term potentiation in freely moving rats,” The Journal of Neuroscience, vol. 17, no. 9, pp. 3303–3311, 1997.
- A. Rodríguez-Moreno, A. Sistiaga, J. Lerma, and J. Sánchez-Prieto, “Switch from facilitation to inhibition of excitatory synaptic transmission by group I mGluR desensitization,” Neuron, vol. 21, no. 6, pp. 1477–1486, 1998.
- J. Cartmell and D. D. Schoepp, “Regulation of neurotransmitter release by metabotropic glutamate receptors,” Journal of Neurochemistry, vol. 75, no. 3, pp. 889–907, 2000.
- I. Brabet, S. Mary, J. Bockaert, and J.-P. Pin, “Phenylglycine derivatives discriminate between mGluR1- and mGluR5-mediated responses,” Neuropharmacology, vol. 34, no. 8, pp. 895–903, 1995.
- J. W. Lazarewicz, A. Ziembowicz, E. Matyja, A. Stafiej, and E. Zieminska, “Homocysteine-evoked 45Ca release in the rabbit hippocampus is mediated by both NMDA and group I metabotropic glutamate receptors: in vivo microdialysis study,” Neurochemical Research, vol. 28, no. 2, pp. 259–269, 2003.
- S. A. Lipton, “Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond,” Nature Reviews Drug Discovery, vol. 5, no. 2, pp. 160–170, 2006.
- Y. Gilgun-Sherki, H. Panet, E. Melamed, and D. Offen, “Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis,” Brain Research, vol. 989, no. 2, pp. 196–204, 2003.